Breaking News Instant updates and real-time market news.

PCRX

Pacira

$35.65

-1.05 (-2.86%)

, HRTX

Heron Therapeutics

$29.40

0.3 (1.03%)

15:01
04/12/18
04/12
15:01
04/12/18
15:01

Draft bill could be good for Heron, seems to exclude Pacira drug, says Cowen

Cowen analyst Boris Peaker said a draft bill creating a pass-through payment for non-opioid analgesics as part of surgical procedures appears to exclude Pacira's (PCRX) Exparel, but could benefit Heron Therapeutics' (HRTX) HTX-011. He also noted, though, that several bills would promote the use of local anesthetics. The House E&C committee is planning to move into more formal legislative drafting mode with the goal of reporting legislation out before Memorial Day, Peaker added.

PCRX

Pacira

$35.65

-1.05 (-2.86%)

HRTX

Heron Therapeutics

$29.40

0.3 (1.03%)

  • 16

    Apr

  • 17

    Apr

  • 18

    Apr

  • 25

    Apr

  • 27

    Apr

  • 08

    May

PCRX Pacira
$35.65

-1.05 (-2.86%)

04/10/18
MZHO
04/10/18
NO CHANGE
Target $35
MZHO
Buy
Pacira label changes positive for Heron, says Mizuho
Mizuho analyst Difei Yang views FDA approval of Pacira Pharmaceuticals (PCRX) Exparel in nerve block as positive for Heron Therapeutics' (HRTX) HTX-011. The FDA updated the label information of Exparel to include detail on the opioid sparing properties of the drug, which appear "modest and potentially not clinically meaningful," Yang tells investors in a research note. This is in contrast to HTX-011, which has demonstrated "superior opioid sparing properties" in a number of studies including the latest Phase 3 trials, the analyst contends. Yang keeps a Buy rating on Heron with a $35 price target.
04/09/18
BMOC
04/09/18
NO CHANGE
Target $34
BMOC
Market Perform
Pacira price target raised to $34 at BMO Capital after Exparel approval
BMO Capital analyst Gary Nachman raised his price target on Pacira to $34 from $31, citing Friday's announcement of FDA approval of an upper extremity nerve block indication for Exparel on the PDUFA. Nachman says this was a "surprising outcome" given a negative panel decision in February, but adds that the indication is also narrow in that it is "limited to an intrascalene brachial plexus block". The analyst keeps his Market Perform rating on Pacira, stating that while Exparel is a " solid product for post-surgical pain, further penetration is challenging and consensus expectations remain high".
04/09/18
HCWC
04/09/18
NO CHANGE
Target $48
HCWC
Buy
Pacira price target raised to $48 from $45 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat raised his price target for Pacira Pharmaceuticals to $48 after the FDA approved an additional "narrow" nerve block indication for Exparel. The FDA added a specific interscalene brachial plexus block indication for regional anesthesia, effectively an indication for shoulder replacement or rotator cuff repair, Livnat tells investors in a research note. While a broad general nerve block indication would have been best case, and Pacira has to be careful not to promote off-label, this is still an "important positive," the analyst contends. He reiterates a Buy rating on Pacira shares.
04/09/18
JPMS
04/09/18
NO CHANGE
JPMS
Neutral
Pacira nerve block approval a 'clear positive,' at JPMorgan
In a research note partially titled "Something's Better Than Nothing," JPMorgan analyst Chris Schott says Friday night's FDA approval for nerve block is a "clear positive" for Pacira Pharmaceuticals. He notes that the Street broadly expected a Complete Response Letter for Exparel in this indication. While the approval does not include a broad nerve block label, it does allow Pacira to target 1M shoulder blocks performed annually, Schott tells investors. However, the Exparel label update also included several failed nerve block studies that should limit off label use of the drug, the analyst adds. He keeps a Neutral rating on Pacira.
HRTX Heron Therapeutics
$29.40

0.3 (1.03%)

04/09/18
PIPR
04/09/18
NO CHANGE
Target $44
PIPR
Overweight
Piper reiterates Overweight on Pacira after 'watershed' nerve block approval
FDA approval of Pacira Pharmaceuticals' (PCRX) Exparel as a brachial plexus block "is something of a watershed" in that the agency has never before approved any local or regional anesthetic for a single, specific setting, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the approval suggests an increasingly aggressive FDA approach towards the opioid crisis. Amsellem points out, however, that feedback from his surgeon survey suggests a "strong degree of enthusiasm" for Heron Therapeutics' (HTRX) HTX-011. However, the feedback also indicates that non-opioid, post-operative pain space is not a zero-sum game, the analyst writes. He believes Exparel can grow "even amid greater competition." Amsellem reiterates an Overweight rating on Pacira with a $44 price target.
04/05/18
EVER
04/05/18
INITIATION
Target $56
EVER
Outperform
Heron Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Joshua Schimmer started Heron Therapeutics (HRTX) with an Outperform rating and $56 price target. He said that given the marked differentiation versus Pacira's (PCRX) Exparel, peak sales for Heron's HTX-011 could approach $2.5B, while Sustol/Cinvanti could add another $300M at peak. These estimates could drive a valuation potentially approaching $11B, or nearly $175 per share, in a bullish scenario, said Schimmer.
04/05/18
LSCM
04/05/18
NO CHANGE
Target $42
LSCM
Buy
Heron 'ready for liftoff' after secondary offering, says Lake Street
Lake Street analyst Bruce Jackson updated his model for Heron Therapeutics following the recently completed stock offering. In a research note partially titled, "Fuel Tank Filled, Ready For Lift Off," the analyst reiterates a Buy rating on Heron with a $42 price target. New Phase 3 data for HTX-011 demonstrated statistically significant reductions in pain intensity and opioid use through 72 hours post-surgery compared to placebo and the current standard of care, bupivacaine, Jackson writes. He notes that management believes the data support an opioid-sparing labeling claim for HTX-011. This would provide a significant competitive advantage, the analyst contends.

TODAY'S FREE FLY STORIES

PEP

PepsiCo

$114.99

0.01 (0.01%)

, SODA

SodaStream

$142.36

12.47 (9.60%)

12:08
08/20/18
08/20
12:08
08/20/18
12:08
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened higher…

PEP

PepsiCo

$114.99

0.01 (0.01%)

SODA

SodaStream

$142.36

12.47 (9.60%)

TSLA

Tesla

$302.31

-3.02 (-0.99%)

CBPO

China Biologic

$102.02

9.96 (10.82%)

NKE

Nike

$82.20

2.47 (3.10%)

LCI

Lannett

$5.58

-7.925 (-58.70%)

INFY

Infosys

$20.40

-0.685 (-3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

  • 12

    Sep

  • 02

    Oct

  • 29

    Oct

12:05
08/20/18
08/20
12:05
08/20/18
12:05
General news
Fed's Bostic said the economy doesn't need as much stimulus as it did before »

Fed's Bostic said…

AVNW

Aviat Networks

$16.20

(0.00%)

12:04
08/20/18
08/20
12:04
08/20/18
12:04
Hot Stocks
Aviat Networks introduces online selling with new Aviat store »

Aviat Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFBK

Central Federal

$2.52

(0.00%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Central Federal announces 1-for-5.5 reverse stock split »

Central Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAHO

Tahoe Resources

$3.84

0.06 (1.59%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Tahoe Resources terminates approx. 200 additional Minera San Rafael employees »

Tahoe Resources regrets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$22.66

0.44 (1.98%)

12:01
08/20/18
08/20
12:01
08/20/18
12:01
Hot Stocks
Street Fight: Analysts split on Bloom Energy after IPO »

Several Wall Street…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$8.26

-0.46 (-5.28%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Comstock Resources falls -5.1% »

Comstock Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$46.80

-2.55 (-5.17%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Installed Building Products falls -5.3% »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Nov

LCI

Lannett

$5.55

-7.95 (-58.89%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Lannett falls -58.7% »

Lannett is down -58.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

CATM

Cardtronics

$37.25

0.08 (0.22%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Options
Second day of call buying in Cardtronics »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATV

Acorn International

$22.00

3.14 (16.65%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Acorn International rises 8.7% »

Acorn International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$23.96

2.43 (11.29%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Amneal Pharmaceuticals rises 11.5% »

Amneal Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 12

    Sep

CMCM

Cheetah Mobile

$10.85

1.75 (19.23%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Cheetah Mobile rises 19.5% »

Cheetah Mobile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PCG

PG&E

$45.05

-0.195 (-0.43%)

, EIX

Edison International

$69.44

-0.42 (-0.60%)

11:59
08/20/18
08/20
11:59
08/20/18
11:59
Periodicals
California's Dodd says securitization of PG&E liability mulled, Bloomberg says »

California Senator Bill…

PCG

PG&E

$45.05

-0.195 (-0.43%)

EIX

Edison International

$69.44

-0.42 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IMTE

Integrated Media Technology

$12.20

0.2 (1.67%)

11:58
08/20/18
08/20
11:58
08/20/18
11:58
Hot Stocks
Integrated Media unit enters distribution agreement with Ai Holdings »

Integrated Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$106.76

-0.82 (-0.76%)

11:57
08/20/18
08/20
11:57
08/20/18
11:57
Hot Stocks
Skype's end-to-end encrypted Private Conversations now available for all users »

Microsoft's Skype…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

TSLA

Tesla

$302.49

-2.84 (-0.93%)

11:55
08/20/18
08/20
11:55
08/20/18
11:55
Recommendations
Tesla analyst commentary  »

Tesla may be wise to try…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TSLA

Tesla

$302.35

-2.98 (-0.98%)

11:52
08/20/18
08/20
11:52
08/20/18
11:52
Periodicals
Tesla's lawyers believe SEC 'under pressure' to expdite probe, Gasparino tweets »

FBN's Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PX

Praxair

$157.81

1.86 (1.19%)

, LNEGY

Linde

$0.00

(0.00%)

11:51
08/20/18
08/20
11:51
08/20/18
11:51
Hot Stocks
EU approves proposed merger between Linde, Praxair »

The European Commission…

PX

Praxair

$157.81

1.86 (1.19%)

LNEGY

Linde

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$285.40

0.38 (0.13%)

11:50
08/20/18
08/20
11:50
08/20/18
11:50
Options
Continued interest in end of year call spreads in SPDR 500 Trust options »

Continued interest in end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
08/20/18
08/20
11:50
08/20/18
11:50
General news
Treasury's $96 B 3- and 6-month bill sale was ok »

Treasury's $96 B 3-…

XLU

Utilities SPDR

$54.43

-0.07 (-0.13%)

11:40
08/20/18
08/20
11:40
08/20/18
11:40
Options
Opening call write in SPDR Utility ETF »

Opening call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

IMNP

Immune Pharmaceuticals

$0.00

(0.00%)

11:36
08/20/18
08/20
11:36
08/20/18
11:36
Hot Stocks
Immune Pharmaceuticals granted Orphan Drug Designation for bertilimumab »

Immune Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.